GlaxoSmithKline S.A.E (EGX:BIOC)
Egypt · Delayed Price · Currency is EGP 62.30
+0.04 (0.06%)
At close: Jan 28, 2026
GlaxoSmithKline S.A.E Income Statement
Financials in millions EGP. Fiscal year is January - December.
Millions EGP. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| 3,741 | 2,991 | 2,240 | 1,823 | 1,812 | 1,993 | |
Revenue Growth (YoY) | 33.27% | 33.51% | 22.87% | 0.62% | -9.07% | 16.95% |
Cost of Revenue | 3,143 | 2,057 | 1,451 | 1,266 | 1,105 | 1,256 |
Gross Profit | 597.87 | 933.94 | 789.12 | 557.4 | 706.66 | 737.06 |
Selling, General & Admin | 394.73 | 406.75 | 366.27 | 326.91 | 409.16 | 438.5 |
Other Operating Expenses | 37.25 | 36.68 | -7.32 | 204.15 | 24.56 | 39.18 |
Operating Expenses | 429.81 | 508.07 | 340.29 | 542.07 | 464.5 | 534.55 |
Operating Income | 168.06 | 425.87 | 448.83 | 15.33 | 242.16 | 202.51 |
Interest Expense | -13.23 | -10.6 | -37.96 | -33.5 | -48.67 | -79.91 |
Interest & Investment Income | 49.45 | 78.28 | 42.15 | - | 0.26 | 0.54 |
Earnings From Equity Investments | - | 1 | -18.12 | 12.15 | -9.21 | -19.49 |
Currency Exchange Gain (Loss) | 14.08 | -147.63 | -169.75 | 34.53 | -5.39 | -11.91 |
EBT Excluding Unusual Items | 218.36 | 346.91 | 265.15 | 28.5 | 179.13 | 91.75 |
Impairment of Goodwill | - | - | -137.65 | -101 | - | - |
Gain (Loss) on Sale of Assets | -2.19 | -2.4 | 0.17 | 5.94 | 0.24 | 0.15 |
Legal Settlements | -5.79 | -5.79 | -7.94 | 3.61 | - | - |
Pretax Income | 210.38 | 338.72 | 119.74 | -62.94 | 179.37 | 91.9 |
Income Tax Expense | 112.01 | 164.74 | 59.26 | 50.87 | 24.74 | 63.75 |
Earnings From Continuing Operations | 98.37 | 173.98 | 60.47 | -113.81 | 154.63 | 28.15 |
Earnings From Discontinued Operations | - | - | - | 849.21 | - | - |
Net Income to Company | 98.37 | 173.98 | 60.47 | 735.4 | 154.63 | 28.15 |
Minority Interest in Earnings | -0.01 | -0 | -0.02 | -0.02 | 0.01 | -0.02 |
Net Income | 98.36 | 173.98 | 60.46 | 735.38 | 154.64 | 28.13 |
Net Income to Common | 98.36 | 173.98 | 60.46 | 735.38 | 154.64 | 28.13 |
Net Income Growth | -17.73% | 187.78% | -91.78% | 375.56% | 449.70% | -80.27% |
Shares Outstanding (Basic) | 84 | 84 | 84 | 84 | 84 | 84 |
Shares Outstanding (Diluted) | 84 | 84 | 84 | 84 | 84 | 84 |
EPS (Basic) | 1.17 | 2.08 | 0.72 | 8.81 | 1.85 | 0.34 |
EPS (Diluted) | 1.17 | 2.08 | 0.72 | 8.81 | 1.85 | 0.34 |
EPS Growth | -18.29% | 187.78% | -91.78% | 375.56% | 449.70% | -80.27% |
Free Cash Flow | -198.17 | -528.49 | 225.2 | 987.26 | 156.43 | -54.84 |
Free Cash Flow Per Share | -2.36 | -6.33 | 2.70 | 11.82 | 1.87 | -0.66 |
Dividend Per Share | - | - | 0.750 | - | 0.750 | - |
Gross Margin | 15.98% | 31.23% | 35.23% | 30.57% | 39.00% | 36.99% |
Operating Margin | 4.49% | 14.24% | 20.04% | 0.84% | 13.36% | 10.16% |
Profit Margin | 2.63% | 5.82% | 2.70% | 40.33% | 8.53% | 1.41% |
Free Cash Flow Margin | -5.30% | -17.67% | 10.05% | 54.15% | 8.63% | -2.75% |
EBITDA | 213.43 | 465.79 | 482.88 | 48.6 | 278.32 | 230.91 |
EBITDA Margin | 5.71% | 15.57% | 21.55% | 2.67% | 15.36% | 11.59% |
D&A For EBITDA | 45.37 | 39.93 | 34.05 | 33.27 | 36.16 | 28.4 |
EBIT | 168.06 | 425.87 | 448.83 | 15.33 | 242.16 | 202.51 |
EBIT Margin | 4.49% | 14.24% | 20.04% | 0.84% | 13.36% | 10.16% |
Effective Tax Rate | 53.24% | 48.64% | 49.50% | - | 13.79% | 69.37% |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.